Boston, Mass. — January 24, 2020 — Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.
Data to be presented at the conference showcase how Decibel’s drug discovery and translational platform is enabling the development of an array of therapeutic programs, including DB-020 to treat cisplatin-induced ototoxicity and a gene therapy to treat congenital deafness caused by a deficiency in the otoferlin gene. In an invited symposium, Jonathon Whitton, Au.D., Ph.D., director of clinical development, will highlight how Decibel has leveraged its industry-leading, single-cell genomics and bioinformatics capabilities as part of a broader gene therapy platform to optimize therapeutic solutions for hearing loss and balance disorders.
“Over the past year, we have made significant advances in a number of our programs. These developments demonstrate the strength of our unique approach and will continue to enable our efforts in restoration and regenerative medicine approaches to the inner ear,” said John Lee, executive vice president, pharmaceutical development.
The Decibel team will have a total of eight posters and presentations during this year’s meeting.
SYMP 12 | Moving Gene Therapies for Hearing Loss into the Clinic
Date & Time: Saturday, January 25, 3:15 p.m. PT
PD 35 | Dissecting the Differentiation Fates of Hair Cells in the Vestibular Sensory Epithelia during Mouse Inner Ear Development using Single Cell Transcriptomics
Date & Time: Sunday, January 26, 11:00 a.m. PT
PS 60 | Development of Middle-Ear-Muscle Reflex (MEMR) Biomarker in Mouse
PS 143 | Multivariate Polygenic Risk Scores Identify Individuals At-Risk for and Protected from Hearing Loss
PS 184 | Natural History and Disease Progression in Two Rodent Models of Monogenic Hearing Loss
PS 463 | DB-020 Protects Cells from Cisplatin Cytotoxicity in vitro and Hair Cells in a Guinea Pig Model of Cisplatin Induced Ototoxicity
PS 692 | Tailored AAV-based Transgene Expression in the Inner Ear with Cell Type-Specific Promoters
PS 714 | Characterization of an Acute and Cyclic Cisplatin-Induced Hearing Loss in Male Fischer-344 Rats
About Decibel Therapeutics, Inc.
Decibel Therapeutics, a development-stage biotechnology company, has established the world’s first comprehensive drug discovery, development and translational research platform for hearing and balance disorders. Decibel is advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibel’s lead therapeutic candidate, DB-020, is being investigated for the prevention of ototoxicity associated with cisplatin chemotherapy. For more information about Decibel Therapeutics, please visit decibeltx.com or follow @DecibelTx.
Matthew Corcoran, Ten Bridge Communications